RxDoctor Payments DataLook up a doctor →

Manjusha Kota, MD

Hematology & Oncology · Hot Springs, ARNPI 1629175922

Payments from drug & device makers

$6,182in general payments, 2019–2025

Across 369 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1K
  • Novartis$608
  • Pfizer$472
  • Amgen$278
  • Incyte Corporation$264
  • E.r. Squibb & Sons, L.L.C.$254
  • plus $3K from 49 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck75$1,170
Novartis35$608
Pfizer30$472
Amgen15$278
Incyte Corporation15$264
E.r. Squibb & Sons, L.L.C.20$254
Eisai Inc.12$230
Johnson & Johnson(2 entities)11$181
EMD Serono, Inc.10$167
AstraZeneca(2 entities)10$164
Foundation Medicine, Inc.7$159
GSK10$158
Sanofi6$156
Lilly USA, LLC9$150
Bayer10$149
Exelixis Inc.8$139
Regeneron Healthcare Solutions, Inc.6$124
Bristol Myers Squibb6$93
Clovis Oncology, Inc.8$89
Karyopharm Therapeutics Inc.5$88
Ipsen Biopharmaceuticals, Inc5$82
Boehringer Ingelheim4$76
Iovance Biotherapeutics, Inc.3$74
Daiichi Sankyo Inc.3$57
Pharmacosmos Therapeutics Inc.3$49
Gilead3$48
Astellas Pharma US Inc3$46
AMAG Pharmaceuticals, Inc.3$44
AbbVie2$39
AVEO Pharmaceuticals, Inc.2$38
Mirati Therapeutics, Inc.2$36
Takeda Pharmaceuticals U.S.A., Inc.1$36
Syndax Pharmaceuticals, Inc.1$34
Array Biopharma Inc2$33
Acceleron Pharma, Inc.2$31
Geron Corporation1$26
Shield Therapeutics Inc1$24
Seagen Inc.2$24
Epizyme, Inc.2$24
Azurity Pharmaceuticals, Inc.1$23
Dova Pharmaceuticals1$22
Deciphera Pharmaceuticals Inc.1$22
Stemline Therapeutics Inc.1$20
Tempus AI, Inc1$20
Kyowa Kirin, Inc.1$18
Genentech USA, Inc.1$18
Sobi, Inc1$17
Genmab U.S., Inc.1$16
Blue Earth Diagnostics1$16
Invivyd Inc1$15
Pharmacyclics LLC, An Abbvie Company1$14
Puma Biotechnology, Inc.1$14
Caris MPI, Inc.1$14
Lexicon Pharmaceuticals, Inc.1$12
Fortovia Therapeutics, Inc.1$7

How this compares

$6,182 in reported general payments places this provider in the 45th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024
$1,174,617
Medicare patients
301
Services billed
102,728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Hot Springs

See the full list for Arkansas →

Where these figures come from

Is this you, or does something look wrong? →